C4 Therapeutics, Inc. (CCCC)
3.14
+0.29
(+10.18%)
USD |
NASDAQ |
Oct 09, 14:29
C4 Therapeutics Profit Margin (Quarterly) : -355.9% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -355.9% |
| March 31, 2026 | -408.5% |
| December 31, 2025 | -186.0% |
| September 30, 2025 | -286.4% |
| June 30, 2025 | -402.6% |
| March 31, 2025 | -363.7% |
| December 31, 2024 | -667.8% |
| September 30, 2024 | -160.6% |
| June 30, 2024 | -147.6% |
| March 31, 2024 | -933.2% |
| December 31, 2023 | -1.07K% |
| September 30, 2023 | -244.2% |
| June 30, 2023 | -1.35K% |
| March 31, 2023 | -925.2% |
| Date | Value |
|---|---|
| December 31, 2022 | -1.30K% |
| September 30, 2022 | -473.2% |
| June 30, 2022 | -198.1% |
| March 31, 2022 | -413.1% |
| December 31, 2021 | -77.99% |
| September 30, 2021 | -290.4% |
| June 30, 2021 | -230.9% |
| March 31, 2021 | -282.4% |
| December 31, 2020 | -263.8% |
| September 30, 2020 | -258.5% |
| June 30, 2020 | -111.6% |
| March 31, 2020 | -174.8% |
| December 31, 2019 | -122.1% |
| September 30, 2019 | -188.2% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | -1.39K% |
| Arrowhead Pharmaceuticals, Inc. | -237.8% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | -2.15K% |
| Sarepta Therapeutics, Inc. | -1.22% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -47.54% |
| Return on Assets | -31.26% |
| Return on Invested Capital | -37.11% |
| Gross Profit Margin (Quarterly) | 73.05% |
| Operating Margin (Quarterly) | -397.9% |
| Return on Net Operating Assets | -200.6% |